LungLife AI, Inc.
(the "Company" or "LungLife")
Notice of Results
Investor Presentation
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, will announce its full year results for the year ended 31 December 2022 on Monday 20 February 2023.
Investor presentation
Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial Officer, will be hosting a live online presentation relating to the full year results via the Investor Meet Company platform at 4.30pm (GMT) on 20 February 2023.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and register for the presentation here. Investors who already follow LungLife on the Investor Meet Company platform will automatically be invited.
A recording of the presentation and a PDF of the slides used will also be available on the LungLife website: https://investors.lunglifeai.com/media/
For further information please contact:
| LungLife AI, Inc. | |
| Paul Pagano, CEO | Via Walbrook PR |
| David Anderson, CFO |
|
|
|
|
| Investec Bank plc (Nominated Adviser & Broker) | Tel: +44 (0)20 7597 5970 |
| Virginia Bull / Cameron MacRitchie | |
| | |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com |
| Paul McManus / Alice Woodings / Phillip Marriage | Mob: 07980 541 893 / 07407 804 654 / 07867 984 082 |
About Lunglife AI
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.